

ANIMAL HEALTH INVESTMENT Europe

Kisaco Research is proud to announce the 12 companies selected to present at the Animal Health Investment Europe **Emerging Company Showcase.**



Visit www.animalhealthevent.com for more information

Headline Sponsor:



Associate Partners:



A Special Thank-You to the SELECTION COMMITTEE



Julia Stephanus
Founder and
President
Avviare



Matthias Hofer
Partner
Stonehaven
Consulting



Maarten Goossens
Principal
anterra capital



Simon Mason
Business Development
Manager, Animal Health
Division
Benchmark
Animal Health



Ronan Molloy
President
INNOVATION
STOCKYARD
DRIVING IDEAS TO MARKET



Michael Hemprich
Head of Business
Development
IDT



Paul Dick
President
Pda
Paul Dick & Associates Ltd.



Charles Hoare
Head of Global Healthcare
STIFEL

About the Emerging COMPANY SHOWCASE

Central to this Summit is the Innovation Showcase: a presentation of new and innovative technologies within the livestock, aquaculture and companion animal health markets.

Our talented Selection Committee have hand-pick 12 emerging companies from over 30 applications to present on-site to our audience. These presentations will showcase the innovation and opportunity that the 12 emerging companies bring to their various markets.

Our 12 finalists, plus almost 100 additional emerging companies will be available for 20-minute private meetings with other attendees throughout the event using our networking platform.

Want to join them on-site?

REGISTER TODAY



Animal Health Europe Emerging COMPANY PROFILES



Dominique Weill

Title

ANI Animal Health



ANI Animal Health and their product:

ANI Animal Health is bringing a ground-breaking new family of Active Nutrigenomic Ingredients (natural micronutrients combined to positively affect gene expression), from the Human side to the production animal industry.

As early as 1990, initial research activities were started in the field of functional micronutrition. In 2011, ANI was formed and is active in the field of Nutrigenomics on the human side. The company's association with leading scientists (e.g., Prof Dr Walter Wahli) as well as leading Universities in Switzerland has helped the company to develop science based health products and to register a number of patents as a result of its research and activities.

Animal Health will be an additional area of value for the company with a number of performance trials in pigs, piglets and cows showing promising improvements to FCR and mortality reduction in pigs & piglets as well as significant reduction of mastitis in cows.

What makes ANI Animal Health unique?

The company provides an additional tool to farmers to help them replace antibiotics in production animals. We will compete with other non-antibiotic feed additives. Our USP is an effective, well described and well understood product, backed by science and strong IP.

Their strategic intent:

ANI Animal Health is currently in formation, as a spin-off from ANI, and will be operational by the end of 2017, including its own Animal Health specific management team and BoD.

By presenting as part of the Innovation Showcase, the company aims to achieve two things:

- Test its ideas with a larger market audience and invite feedback and reactions to its strategy and unique business proposition,
- Make the (Animal Health) investment community aware of a potentially attractive and new funding opportunity - the company would officially launch at the event and start its roadshow for Series-A funding after the event.

Animal Health Europe Emerging COMPANY PROFILES



Jimmy Owens

VP, Global Product Launch

Ascus Biosciences



Jimmy Owens joined Ascus in June 2017. He is responsible for commercializing Ascus' portfolio of first-in-class endomicrobial products around the world. Ascus' proprietary technology platform, focused on the emerging science of endomicrobial ecology, illuminates an animal's microbiome to improve animal health and performance.

Before joining Ascus, he spent over a decade at Eli Lilly & Company and Elanco in roles across finance, strategy & operations, productivity & transformation, and sales leadership. Most recently, he led Elanco's US Dairy sales team while launching Imrestor, the first and only immune restorative for periparturient dairy cows and heifers. Through his roles, Jimmy has gained a deep understanding of innovation-driven growth and what it takes to bring a product to market.

Ascus Biosciences and their product:

Ascus is pioneering the emerging science of endomicrobial ecology to illuminate microbial communities within animals and its influence on health and performance. Ascus has a broad pipeline of endomicrobial products across livestock and companion animals. Galaxis for Dairy is their lead product and could launch as early as 2018.

What makes Ascus Biosciences unique?

Three attributes make Ascus unique:

- 1. Our Science (Endomicrobial Ecology):** Our platform, focused on endomicrobial ecology, enables broad product development across all species and affords novel insights to shape the future of animal health.
- 2. Our Products (Endomicrobial Supplements):** Using native microbes, with a proven mode of action, results in inherently safe & effective products that produce measurable, repeatable and significant efficacy. These first-in-class products do not require changes to current feeding systems.
- 3. Our Intellectual Property:** We have issued and pending patents that aim to protect our underlying platform and the uses of microbial targets for product development.

Their strategic intent:

Our intent for participating in the innovation showcase is two-fold. First, we want to raise awareness for microbiology in animal health, something we believe represents the next wave of innovation in the industry. Second, as we scale, we are open to potential business development opportunities in select species and/or geographies.

Animal Health Europe Emerging COMPANY PROFILES



askel
healthcare

Virpi Muhonen
CEO, Co-Founder
Askel Healthcare Ltd.



Virpi is passionate about regenerative medicine, especially regeneration of articular cartilage. She holds a PhD in cell biology and has a strong background in orthopaedic research. She is the CEO of Askel Healthcare Ltd, a med tech company focusing on cartilage regeneration in companion animals.

Askel Healthcare and their product:

Cartilage damage results in pain, lameness and predisposition to arthritis. Despite the high prevalence of the problem, there are no treatments available to restore and maintain the functionality of the tissue. Askel Healthcare has developed a medical device (COPLA Scaffold), to regenerate the cartilage tissue permanently.

What makes Askel Healthcare unique?

Askel Healthcare's core technology is a medical device, called COPLA Scaffold, designed for cartilage repair of weight-bearing joints. The founders of Askel Healthcare have a strong scientific R&D background and they have worked together over eight years on the development of this cartilage regeneration device. Cartilage tissue has extremely low self-reparative potential and if an injury is left untreated, it's considered the first step in the joint degenerative process, leading to debilitating osteoarthritis. The use of COPLA Scaffold provides a unique long-term treatment solution, unlike current methods with only symptom-relieving and temporary outcomes. COPLA Scaffold is the only medical device capable of true cartilage regeneration.

Their strategic intent:

We are looking for 1) equity investment and 2) strategic partners to scale-up manufacturing and to reach global markets. Thus, in the event, we hope to identify both investors and distributors with whom we can make Askel Healthcare's COPLA Scaffold the primary therapeutic intervention for cartilage damage globally.

Animal Health Europe Emerging COMPANY PROFILES



Bertrand Mérot, PhD, MBA

Founder & Chief Executive Officer
Bio-Sourcing

Marie-Pascale Tiberghien, DVM

Senior project Director
Bio-Sourcing



Bio-Sourcing and their product:

Bio-Sourcing contributes to One Health Challenge by developing suitably designed Biopharmaceuticals to the Animal Health Industry. We implement cutting edge but validated technologies that we are continuously improving to reduce cost for large volume of bioproduction.

What makes Bio-Sourcing unique?

Bio-Sourcing has a right combination of Assets to be an innovative leader in Animal Health Industry:

- A set of Exclusive Innovative Technologies allowing Bio-sourcing to provide the best bioproduction solutions.
- An agreement with a leading player in Animal Health for developing proteins
- A promising Bio-Sourcing internal pipeline validated with the Industry.
- A Partnership Business Model, sharing risks and limiting development costs.
- An experienced and expert Team in Veterinary product development, a knowledgeable Scientific Advisory Board, a strong Board of Directors.
- Significant added value for investors with clear strategy

Their strategic intent:

- Bio-Sourcing is offering an opportunity to invest in our current round B fundraising
- Bio-Sourcing is looking for partnerships for co-development of high potential biopharmaceuticals
- Bio-Sourcing is interested by strategic alliance with Industry and Biotech using Bio-Sourcing's unique bioproduction platforms (BioMilk™; Zoobodies®)

Dr. Bertrand Mérot was held Executive Senior positions in Biotech industry as in particular Vice President at LFB Biotechnologies and Oncodesign, Board Member of France Biotech or GTC. He also founded and managed Meristem Therapeutics

Dr Marie-Pascale Tiberghien has over 25 years broad experience in the veterinary industry, notably with Merial and Bayer Animal Health in R&D, Manufacturing and Global Marketing positions.

Animal Health Europe Emerging COMPANY PROFILES



Prof. Jeroen Kortekaas PhD

CEO
BunyaVax



BunyaVax and their product:

BunyaVax is a Dutch biotech company that commercializes unprecedented Plug & Play vaccine platform technology. The technology allows for cost-effective and rapid generation of vaccines against endemic and newly emerging viruses. The platform is particularly suitable for the prevention of emerging diseases of livestock.

What makes BunyaVax unique?

BunyaVax is the first company to develop Plug & Play vaccine technology that generates inherently safe and efficacious vaccines within a timeframe of 20 weeks. Especially during outbreaks of new and life-threatening virus strains, rapid and affordable vaccination of the at-risk animals is essential. The Plug & Play feature allows for introduction of any desired gene into the RNA particle genome. Vaccination with BunyaVax RNA particles was shown to induce durable protection against highly pathogenic viruses in both laboratory animals and target animals.

Their strategic intent:

The goal is to partner with an animal-health company for further development of the proprietary technology towards effective application for veterinary use.

Prof. Jeroen Kortekaas, PhD has been CSO of BunyaVax since the start of the company, and has steered the development of the BunyaVax technologies.

Jeroen is Professor of Veterinary Arbovirology at Wageningen University. He is also Head of the Bunyavirus Research Group at Wageningen Bioveterinary Research. Previous positions include Project leader at the Central Veterinary Institute, Wageningen University and Postdoctoral researcher at Utrecht University. Jeroen received his PhD from the University of Utrecht after completing his thesis on the "Vaccine potential of iron-regulated outer membrane receptors of *Neisseria meningitidis*".

Jeroen has (co)authored more than 40 publications in peer-reviewed scientific journals and is an inventor on 6 patent applications. Three vaccines that were developed under his supervision were brought beyond the proof of concept phase in collaboration with pharmaceutical companies. One of his major running projects is the Zoonoses Anticipation and Preparedness Initiative (ZAPI: <http://zapi-imi.eu/>), a large ~20m€ project that aims to develop novel pipelines for the development of vaccines and antibodies against emerging zoonotic diseases.

Animal Health Europe Emerging COMPANY PROFILES



Simon Aspland, PhD

Co-Founder and General Manager

Chalante



Chalante and their product:

Chalante invents and develops proprietary nature-inspired parasiticides and feed conversion enhancers, and methods for their manufacture, for the £24 billion animal health industry. Our bioactive molecules, discovered and developed using combinations of chemistry and synthetic biology technologies, are designed to enhance health, performance and well-being of companion and food animals.

What makes Chalante unique?

Chalante's products result from our proprietary use of differentiated and complementary capabilities to address animal health industry channel partners' strategic research and product interests. Complex nature-inspired molecules are fertile origins to meet industry validated target product profiles, but can be challenging to work with. Chalante overcomes these challenges through selectively applying combinations from an innovative mix of technologies including: cutting edge total synthesis, semi-synthesis, mutasynthesis, biotransformation and directed mutation of microbes useable in fermentation. Validation of this approach comes from the founders' successful use of it to create and develop AgriMetis, a company they cofounded to develop crop protection products.

Simon is a cofounder and General Manager of Chalante. Previously, he has co-founded and helped manage four biotechnology companies firstly Stell (xeno-transplantation) then as part of the Acidophil team: Arginetix (cardiovascular health), ZuvaChem (industrial biotechnology) and AgriMetis (crop protection). Originally a molecular biologist, his corporate experience comes from working in the US and Europe.

Their strategic intent:

Chalante is raising Series A funds to advance development of programs initiated 18 months ago supported by founders and grants. An early Series A objective is to address industry partner needs, close one or more corporate partnerships and maximize the value and prospects for our growing portfolio of product opportunities.

Animal Health Europe Emerging COMPANY PROFILES



Lucia Martini

Associate Director, Business Development
Diversigen, Inc.

Diversigen and their product:

The human microbiome market is expected to reach \$658m by 2023 driven mainly by probiotics. Investment in Animal Health is only just getting started and offers high potential to deliver a new class of health product to the industry. Diversigen is a one-stop-shop for microbiome exploration. We serve a portfolio of Big Pharma human health clients. The company was born out of Baylor College of Medicine and the Centre for Metagenomics and Microbiome Research (CMMR). We are receiving a growing number of requests from Animal Health pharma companies. Diversigen's core technology: Sequencing, Bioinformatics and germ-free specifically tailored to microbiome needs.

What makes Diversigen unique?

The Diversigen laboratory is collocated with CMMR, giving access to world leading microbiome research facilities and state-of-the-art platforms and technology.

Their strategic intent:

To leverage their success in Human Health and launch a dedicated offering to the Animal Health industry.

Animal Health Europe Emerging COMPANY PROFILES



George Brownlee

CEO, Founder

Farmvet Systems Ltd



As a farmer's son and experienced farm animal veterinarian, George has gained valuable first-hand experience of the industry from the bottom up. He recognised a significant issue which affects the entire animal health industry. Therefore in 2010 he left practice and founded Farmvet Systems to unlock the 'black box' which keeps farm and vet information shrouded in mystery and fragmented in disparate silos of data.

As a passionate entrepreneur his determination in this area has seen over 1000 of his veterinary colleagues and thousands of their farm clients in the UK and Ireland gain access to previously unavailable, unconnected data across millions of animals through the company's web and mobile app software and data integration platform. Equipping vets at every level of their work and business from pen-side decision support through to practice level business insights.

Farmvet Systems and their product:

Without data, farm vets can't work efficiently to find and convert opportunities. Our VetIMPRESS platform provides actionable insights for vets. Supporting cow-side decisions, farmer alerts, vet reporting and practice business intelligence, thereby boosting the entire animal health industry.

Our technology automatically brings data from disparate sources. Cleansing it and creating standardised, integrated datasets for delivery to farm animal vets and their farm clients. This provides highly actionable insights for vets and practices to identify and demonstrate improvements to animal health that will have a return on investment for their farm client.

1000 farm animal vets across the UK and Ireland are already using the software to manage their practice business and work with their suppliers to be the best vets they can be on farm.

www.vetimpress.com

What makes VetIMPRESS unique?

Our technology platform which is permissioning, acquiring, standardising and integrating data across our customer network of vets and their farm clients has been built from the ground up to fit the needs of the farm animal health industry. It integrates with existing technologies across the sector such as government databases, vet practice management systems, farm management systems, veterinary laboratories and more. This breadth of data and features perfectly suited to the everyday work of farm animal vets means no other service has the level of unique, granular insights we provide right down to individual animal level with the network of vets on farm ready to take action

Their strategic intent:

We are open to business development opportunities with global industry players who gain from farm vets working smarter. We are also seeking Series A investment to build out the next stage of the company as we scale the technology and take on new territories.

Animal Health Europe Emerging COMPANY PROFILES



Marc Peter Maserati Jr

Director

In Vitro Clonagem Animal



Marc Peter Maserati Jr has been a Director of In Vitro Clonagem Animal S/A since 2014. He is responsible for cloned and ICSI embryo production for Brazil and the South American market as well as research and development. He has 17 years of experience working in the fields of reproductive biology, animal cloning and stem cell biology. Marc holds a Masters degree in Animal Science and Animal Biotechnology from the University of Massachusetts, Amherst.

In Vitro Clonagem Animal and their product:

In Vitro Clonagem Animal is an animal cloning company based in Mogi Mirim, São Paulo, Brazil. A privately-owned company founded in 2005, we will now use molecular biology and cloning techniques to create cloned transgenic mammals for the production of protein for therapeutic use in human and animal.

What makes In Vitro Clonagem Animal unique?

Our company consists of dedicated and detail oriented individuals with experience building an international company. For this product, our animal cloning expertise will be paired with our partner's transgenic expertise to create transgenic mammals for the production of therapeutic proteins expressed in milk. The advantage in our approach is the evaluation of the DNA construct in mammary glands to choose the species best at protein production prior to animal cloning, saving time and money. In this initial venture we will produce the blood clotting factor IX along with the enzyme responsible for converting inactive to active factor IX.

Their strategic intent:

We are currently funded for the initial proof-of-principle work but need investment to bring this product to market. As for funding, we are looking for either a partnership or investment but will also need guidance with government regulations on protein production for clinical use in Brazil and internationally.

Animal Health Europe Emerging COMPANY PROFILES



Natalia Romanova-Mossig

Business Development Director and Co-Founder
N2 Pharma



N2 Pharma and their product:

N2-01 is an injectable drug that significantly increases the effectiveness of artificial insemination in dairy cattle. When used on more than 1,300 repeat breeding cows in Russia, N2-01 showed results unprecedented for the industry, increasing effectiveness by at least 50%. The cost of low fertility is £0.5bn per year in the UK alone.

What makes N2 Pharma unique?

- The drug has already been registered in Russia.
- Despite the fact that N2 Pharmaceuticals is at the early development stage for the European registration, it has extensive market usage data showing that N2-01 is safe and effective on target species, which is a rare case in the pharmaceutical industry.
- The drug outperforms other treatments on the market, at a lower cost.
- N2-01 addresses a multi-billion pound problem in Europe and the world

Natalia is an experienced business development specialist with a strong portfolio of international projects under her management in the UK, Russia and Europe. She held positions in management, sales and marketing and managed cross-functional and multinational teams based in the Netherlands and the UK. Her previous roles involved the preparation of strategic development and market penetration plans, as well as the subsequent execution of these strategies. She holds a degree in International Business, Finance and Economics from Manchester Business School.

Natalia, together with the inventor of the technology, established N2 Pharmaceuticals with the intention of bringing it to the European market.

Their strategic intent:

N2 Pharmaceuticals wishes to reach the vast European dairy market through selling a European license to a major Pharmaceutical company. The company is seeking equity funding as well as strategic partnership in order to progress in its European development and maximise the value of the deal.

Animal Health Europe Emerging COMPANY PROFILES



Paratin and their product:

Paratin offers a non-antibiotic treatment for mastitis, aligned with current regulatory trends, decreasing the economic loss related with antibiotics by enabling the milking of the uninfected mammary glands. It intensifies the affinity of the immune-system towards the pathogens with zero-risk for induction of drug-resistant bacterial pathogens.

What makes Paratin unique?

Paratin's novel biological non-antibiotic treatment eliminates the E. coli bacteria, reduces severity and shortens the time of inflammatory effects due to Mastitis. It radically reduces the number of active components, improves production capacities thus cutting production costs.

Paratin's Recombinant Multi-Domain (RMD) approach is a non-antibiotic broad-spectrum biological agent composed of several proteins spontaneously immobilized to a carrier. The RMD complex binds specifically to the pathogens and to the lipopolysaccharide (LPS) while stimulating the phagocytosis system of the mammary gland. This dual activity triggers the innate immune system leading to bacterial eradication and full recovery that does not associate with milk loss.

Their strategic intent:

Paratin prioritizes collaboration with leading Animal Health Pharma MNCs that can also serve as potential strategic investors. The technological end-solution we provide can be deployed based on licensing to these MNCs. We seek to engage with them during the event in order to explore such possibilities.

Animal Health Europe Emerging COMPANY PROFILES



Dr. Oswald Lockhoff

Managing Director
SIDANIS Pharma



Oswald Lockhoff has an extensive scientific background and leadership experience in the pharmaceutical industry. Based on this, he founded Sidanis Pharma in 2011 where he is Managing Director and pursues the development of immunotherapeutics against infectious diseases. Prior to this he worked as a freelance consultant for small biotech and pharmaceutical companies. Since 1980 and until 2003 Oswald worked at Bayer as laboratory head and from 1986 as group leader for anti-infectives and other fields of research where he actively participated in the discovery and development of clinical candidates and marketed drugs. He received his PhD in chemistry from Hamburg university and studied business economics. Oswald is the author/co-author of numerous scientific publications and inventor in more than 35 patent applications.

SIDANIS Pharma and their product:

SIDANIS Pharma was founded in 2011 in Hamburg, Germany, as a biopharmaceutical start-up company that discovers and develops immunotherapeutics as next-generation anti-infectives for human and animal health. The drugs will prevent or treat infectious diseases and are to curb the global rise of microbial resistance to antibiotics.

What makes SIDANIS Pharma unique?


We develop a new class of drug molecules - so-called glycoconjugate immunostimulators (GCI) - which selectively activate the immune system of mammals and birds and protect the bodies from infectious incidences. Depending on their structural properties, the drugs either act as host defence modifier which broadly increase the host's natural defence (innate immunity) against a variety of bacteria, fungi or viruses or they specifically augment the immune response as adjuvants in vaccinations (adaptive immunity). Their efficacy and tolerability was proven in many animal models and in a pilot study in swine. Since the drugs have no direct antimicrobial activity, the generation of antimicrobial resistance is unlikely.

Their strategic intent:

SIDANIS is looking for a series A funding from investors. The money will be utilized to develop GCI as novel anti-infectives for animal health to control bacterial infections in livestock (e.g. respiratory and enteral infections, factorial diseases, mastitis) and companion animals. We are open for cooperation with global animal health companies.

Can't join us in London?

ANIMAL HEALTH INNOVATION SERIES:



We'd like to thank our 2018 PARTNERS


Headline Sponsor:



Associate Partners:



Consulting Partner:



A special thanks to Stonehaven Consulting for providing all 12 of the Showcase Presenters with a half-day consulting.

Senior Event Partner:



Event Partners:

